Skip to content

Development and Evaluation of Technical Standards for Diagonosis and Treatment of Integartive Medicine for Insomnia

Development and Evaluation of Technical Standards for Diagonosis and Treatment of Integartive Medicine for Insomnia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003977
Enrollment
Unknown
Registered
2020-09-23
Start date
2020-09-21
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Adults diagnosed with insomnia using the DSM-5 and ICSD-3; 2. Aged 18 to 65 years; 3. Pittsburgh Sleep Quality Index (PSQI) >7 during the screening period and at baseline; 4. Insomnia severity index (ISI)>7 during the screening period and at baseline;; 5. Stable vital signs with certain expression and cognitive ability; 6. Volunteer to participate in this clinical trial and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Participants with other related medical history that may affect sleep including narcolepsy, circadian rhythm sleep disorder, sleepwalking, sleep-related breathing disorder, obstructive or central sleep apnea syndrome, restless legs syndrome, etc.; 2. Participants with sever mental illnesses or emotional and behavior disorder disorder (such as schizophrenia, suicidal tendency or suicide history) in the past year, or long-term use of central nervous system depressant or stimulant drugs; 3. Insomnia caused by other conditions in the past month, such as pain, fever, cough, surgery, interference from the external environment, etc.; 4. Liver function AST and ALT exceed the upper limit of normal reference value by 1.5 times, or Scr exceeds the upper limit of normal reference value. 5. Participants with severe cardiovascular, lung, liver, kidney, endocrine or central nervous system diseases; 6. Drug and alcohol abuse or dependence; 7. Participants with allergic reaction to the test drug or its ingredients; 8. Pregnant or lactating women, women of childbearing age who cannot take contraceptive measures during the trial; 9. Participants participate in other drug clinical trials within the past month; 10. Researchers consider the participant is inappropriate to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Insomnia Severity Index;Pittsburgh sleep quality index;

Secondary

MeasureTime frame
Cornell Medical Index;

Countries

China

Contacts

Public ContactYan Li

Guangzhou University of Chinese Medicine

janeliyan2002@163.com+86 18922108342

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026